SAbDab: The Structural Antibody Database

> Structural Summary

Therapeutic	Bevacizumab
Target	VEGFA
Heavy Chain	EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYLQMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS
Light Chain	DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYSTVPWTFGQGTKVEIK
100% seqID Fv Structure	1bj1 [Fvs: HL, KJ], 7v5n [Fvs: BA, FE]
99% seqID Fv Structure	None
95-98% seqID Fv Structure	1cz8 [Fvs: HL, YX], 6bft [Fvs: AB, HL]

> SAbDab Links

100% seqID Structure	1bj1 [Fvs: HL, KJ]
100% seqID Structure	7v5n [Fvs: BA, FE]
95-98% seqID Structure	6bft [Fvs: AB, HL]
95-98% seqID Structure	1cz8 [Fvs: HL, YX]

> Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Bevacizumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

> 6bft: A/B

Sequence identity: 98.26%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	101	102	103	104	105	106	107	108	109	110	111	112	113
bevacizumab	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	Y	T	F	T	N	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	G	W	I	N	T	Y	T	G	E	P	T	Y	A	A	D	F	K	R	R	F	T	F	S	L	D	T	S	K	S	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	K	Y	P	H	Y	Y	G	S	S	H	W	Y	F	D	V	W	G	Q	G	T	L	V	T	V	S	S
6bft	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	Y	D	F	D	N	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	G	W	I	N	T	Y	T	G	E	P	T	Y	A	A	D	F	K	R	R	F	T	F	S	L	D	T	S	K	S	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	K	Y	P	H	Y	Y	G	S	S	H	W	Y	F	D	V	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
bevacizumab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	S	Q	D	I	S	N	Y	L	N	W	Y	Q	Q	K	P	G	K	A	P	K	V	L	I	Y	F	T	S	S	L	H	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	S	T	V	P	W	T	F	G	Q	G	T	K	V	E	I	K
6bft	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	S	Q	D	I	S	N	Y	L	N	W	Y	Q	Q	K	P	G	K	A	P	K	V	L	I	Y	F	T	D	D	L	H	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	S	T	V	P	W	T	F	G	Q	G	T	K	V	E	I	K

> 1cz8: H/L

Sequence identity: 97.83%

Heavy chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	52A	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	82A	82B	82C	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	100A	100B	100C	100D	100E	100F	101	102	103	104	105	106	107	108	109	110	111	112	113
bevacizumab	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	Y	T	F	T	N	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	G	W	I	N	T	Y	T	G	E	P	T	Y	A	A	D	F	K	R	R	F	T	F	S	L	D	T	S	K	S	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	K	Y	P	H	Y	Y	G	S	S	H	W	Y	F	D	V	W	G	Q	G	T	L	V	T	V	S	S
1cz8	E	V	Q	L	V	E	S	G	G	G	L	V	Q	P	G	G	S	L	R	L	S	C	A	A	S	G	Y	D	F	T	H	Y	G	M	N	W	V	R	Q	A	P	G	K	G	L	E	W	V	G	W	I	N	T	Y	T	G	E	P	T	Y	A	A	D	F	K	R	R	F	T	F	S	L	D	T	S	K	S	T	A	Y	L	Q	M	N	S	L	R	A	E	D	T	A	V	Y	Y	C	A	K	Y	P	Y	Y	Y	G	T	S	H	W	Y	F	D	V	W	G	Q	G	T	L	V	T	V	S	S

Light chain

Position	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107
bevacizumab	D	I	Q	M	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	S	Q	D	I	S	N	Y	L	N	W	Y	Q	Q	K	P	G	K	A	P	K	V	L	I	Y	F	T	S	S	L	H	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	S	T	V	P	W	T	F	G	Q	G	T	K	V	E	I	K
1cz8	D	I	Q	L	T	Q	S	P	S	S	L	S	A	S	V	G	D	R	V	T	I	T	C	S	A	S	Q	D	I	S	N	Y	L	N	W	Y	Q	Q	K	P	G	K	A	P	K	V	L	I	Y	F	T	S	S	L	H	S	G	V	P	S	R	F	S	G	S	G	S	G	T	D	F	T	L	T	I	S	S	L	Q	P	E	D	F	A	T	Y	Y	C	Q	Q	Y	S	T	V	P	W	T	F	G	Q	G	T	K	V	E	I	K

> SAbPred Links

Follow these links to our prediction tools:

Model the variable domain structure with ABodyBuilder2
Test for possible therapeutic developability issues with TAP
Assign canonical forms by sequence with SCALOP
Number the sequences in any numbering scheme with ANARCI: [heavy] [light]

> Metadata

Format	Whole mAb
Isotype	G1
Highest Clinical Trial (Aug '24)	Approved
Estimated Status (Aug '24)	Active
Recorded Developmental Technology
INN Year Proposed	2000
INN Year Recommended	2001
Companies Involved	All Ireland Cooperative Oncology Research Group, ARCAGY/GINECO Group, Austrian Breast & Colorectal Cancer Study Group, Bayer, Beth Israel Deaconess Medical Center, Breast Cancer Research Foundation, Brigham and Women's Hospital, Bristol-Myers Squibb, Cancer and Leukemia Group B, Cancer Research UK, Chugai Pharmaceutical, Cincinnati Children's Hospital Medical Center, Dana-Farber Cancer Institute, Duke University, European Organisation for Research and Treatment of Cancer, European Thoracic Oncology Platform, Genentech, Hackensack University Medical Center, Hoosier Cancer Research Network, Indiana University School of Medicine, Japan Breast Cancer Research Group, M. D. Anderson Cancer Center, Massachusetts General Hospital, Medical University of South Carolina, Melanoma Research Foundation Breakthrough Consortium, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), National Comprehensive Cancer Network, NCIC Clinical Trials Group, North Central Cancer Treatment Group, NSABP Foundation, Ohio State University Medical Center, Peter MacCallum Cancer Centre, Roche, Royal Marsden NHS Foundation Trust, Sanofi, Sarcoma Alliance for Research through Collaboration, SCRI Development Innovations, South Eastern European Research Oncology Group, Spanish Cooperative Group for Digestive Tumour Therapy, Spanish Lung Cancer Group, Stanford University School of Medicine, SWOG, The Catalan Institute of Oncology, UNICANCER, University College London, University of Alabama at Birmingham, University of Arkansas System, University of California Davis, University of Iowa, University of Oklahoma, University of Tennessee, University of Texas M. D. Anderson Cancer Center, US Oncology Research, West German Study Group, Xijing Hospital
Conditions Approved	Breast cancer, Cervical cancer, Colorectal cancer, Glioblastoma, Glioma, Non-small cell lung cancer, Ovarian cancer, Renal cell carcinoma, Fallopian tube cancer, Peritoneal cancer
Conditions Active	Head and neck cancer, Biliary cancer, Brain metastases, Endometrial cancer, Ewing's sarcoma, Gynaecological cancer, Hodgkin's disease, Intestinal cancer, Liver cancer, Liver metastases, Malignant melanoma, Meningioma, Multiple myeloma, Neuroblastoma, Neurofibromatoses, Rectal cancer, Soft tissue sarcoma, Solid tumours, Urogenital cancer, Neoplastic meningitis, Sarcoma
Conditions Discontinued	Carcinoid tumour, Chronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Eye disorders, Gastric cancer, Gastrointestinal stromal tumours, Mesothelioma, Oesophageal cancer, Pancreatic cancer, Prostate cancer, Small cell lung cancer
Notes	Biosimilars available

Thera-SAbDab

BEVACIZUMAB